ArticleJournal of nanobiotechnology2020
Intra-articular delivery of celastrol by hollow mesoporous silica nanoparticles for pH-sensitive anti-inflammatory therapy against knee osteoarthritis.
Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 93 citations in OpenAlex.
- Randomized, single-centre, double-blinded repeated dose investigation of safety and tolerability of ocular administrations of a novel silica eye drop product in healthy volunteers.Acta ophthalmologica · 2026Trial
- Transforming Pediatric Dentistry with Chitosan Gel: Current Evidence and Emerging Trends-A Scoping Review.Materials (Basel, Switzerland) · 2026Review
- Advances in drug delivery systems for Osteoarthritis therapy: exosomes, microparticles, nanoparticles, and hydrogels.Discover nano · 2026Review
- Celastrol-Loaded Liposomal Hydrogel Microneedles for Safe and Effective Treatment of Psoriasis.Biomedicines · 2026Article
- Overcoming the Druggability Hurdles of Celastrol: A Critical Review of Advanced Drug Delivery Strategies.Biomolecules · 2026Review
- Microfluidic methacrylated hyaluronic acid microspheres incorporating MnOMaterials today. Bio · 2026Article
- Smart Nanodelivery Systems for Immunometabolic Modulation in Osteoarthritis.Exploration (Beijing, China) · 2026Review
- Acid-responsive metal organic frameworks with photothermal effects for osteoarthritis multiple therapy.RSC advances · 2026Article
- Microfluidic Nanocomposite Lubricating Microgels Localized Deliver Celastrol for Remodeling the Immune Microenvironment to Enhance Osteoarthritis Treatment.Research (Washington, D.C.) · 2026Article
- Bone-targeted celastrol nanocarrier suppresses osteoclastogenesis in postmenopausal osteoporosis.NPJ science of food · 2025Article
- Immunomodulatory biomaterials for osteoarthritis: Targeting inflammation and enhancing cartilage regeneration.Materials today. Bio · 2025Review
- Biocompatible Mesoporous Materials for Bone Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Nanomedicine for chronic pain management: From pathophysiology to engineered drug delivery systems.Materials today. Bio · 2025Review
- Structural diversity and biological activities of terpenoids derived fromRSC advances · 2025Review
- Therapeutic Controlled Release Strategies for Human Osteoarthritis.Advanced healthcare materials · 2025Review
- Drug Delivery Systems Targeting the Knee Microenvironment: A Prospective Strategy for Knee Osteoarthritis Treatment.Drug design, development and therapy · 2025Review
- Mechanistic Insights Into Celastrol's Anti-Pyroptosis Effects in Osteoarthritis via SIRT2 Upregulation.Mediators of inflammation · 2025Article
- From Physicochemical Constraints to Clinical Prospects of Celastrol: Challenges and Nano Delivery Strategies.International journal of nanomedicine · 2025Review
- Nanotechnology in Orthopedic Care: Advances in Drug Delivery, Implants, and Biocompatibility Considerations.International journal of nanomedicine · 2025Review
- Nanomaterial-Based Drug Delivery Systems Targeting Functional Cells for Osteoarthritis Treatment: Mechanisms, Challenges and Future Prospects.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCelastrol has been proven effective in anti-inflammatory but was limited in the clinic due to the poor solubility and side effects induced by low bioavailability. Osteoarthritis has acidic and inflammatory environment. Our aim was to load celastrol into HMSNs and capped with chitosan to construct a pH-responsive nanoparticle medicine (CSL@HMSNs-Cs), which is of high solubility for osteoarthritis intra-articular injection treatment.
methodsThe CSL@HMSNs-Cs were assembled and the characteristics were measured. The CSL@HMSNs-Cs was applied in vitro in the chondrocytes collected from rats cartilage tissue and in vivo in the MIA induced knee osteoarthritis rats via intra-articular injection. Cytotoxicity assay, pH-responsive release, pain behavior, MRI, safranin o fast green staining, ELISA and western blot analysis were applied to evaluate the bioavailability and therapeutic effect of CSL@HMSNs-Cs.
resultsCSL@HMSNs-Cs was stable due to the protection of the chitosan layers in alkaline environment (pH = 7.7) but revealed good solubility and therapeutic effect in acidic environment (pH = 6.0). The cytotoxicity assay showed no cytotoxicity at relatively low concentration (200 μg/mL) and the cell viability of chondrocytes stimulated by IL-1β was increased in CSL@HMSNs-Cs group. Paw withdrawal threshold in CSL@HMSNs-Cs group is increased, and MRI and Safranin O Fast Green staining showed improvements in articular surface erosion and joint effusion. The upregulated expression levels of IL-1β, TNF-α, IL-6, MMP-3 and MMP-13 and NF-κB signaling pathway of chondrocytes were inhibited in CSL@HMSNs-Cs group.
conclusionHollow mesoporous silica nanoparticles were an ideal carrier for natural drugs with poor solubility and were of high biocompatibility for intra-articular injection. These intra-articular injectable CSL@HMSNs-Cs with improved solubility, present a pH-responsive therapeutic strategy against osteoarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.